G Mantovani, A Coiana, A Massidda, E Proto, C Floris, A Macciò, G Pusceddu, G S Del Giacco
{"title":"白细胞介素2 (IL 2)与癌症。pha激活和非pha激活的癌症患者PBMC对外源性R和非R IL 2的体外反应。","authors":"G Mantovani, A Coiana, A Massidda, E Proto, C Floris, A Macciò, G Pusceddu, G S Del Giacco","doi":"","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":73745,"journal":{"name":"Journal of Experimental Pathology","volume":"3 4","pages":"539-47"},"PeriodicalIF":0.0000,"publicationDate":"1987-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Interleukin 2 (IL 2) and cancer. In vitro response to exogenous R and non-R IL 2 by PHA-activated and non-PHA-activated PBMC from patients with cancer.\",\"authors\":\"G Mantovani, A Coiana, A Massidda, E Proto, C Floris, A Macciò, G Pusceddu, G S Del Giacco\",\"doi\":\"\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":73745,\"journal\":{\"name\":\"Journal of Experimental Pathology\",\"volume\":\"3 4\",\"pages\":\"539-47\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"1987-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Experimental Pathology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Experimental Pathology","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Interleukin 2 (IL 2) and cancer. In vitro response to exogenous R and non-R IL 2 by PHA-activated and non-PHA-activated PBMC from patients with cancer.